Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microtransplantation in Elderly AML (IMCG-EAML)
NCT02171117Phase 3Unknown
- Sponsor
- 307 Hospital of the People's Liberation Army
- Start
- Mar 2014
- Primary completion
- Jun 2018
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of hla-mismatched donor peripheral stem cells in acute myeloid leukemia (AML) (2 arms), sponsored by 307 Hospital of the People's Liberation Army. Primary endpoint: Remission rate at 2 months. Status: unknown.
02
Drugs
hla-mismatched donor peripheral stem cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02171117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02171117.